BRIEF published on 08/01/2025 at 14:05, 1 year 2 months ago CARMAT: Resumption of Quotation and Update on Judicial Recovery Takeover Offer CARMAT Resumption Of Quotation Judicial Recovery Aeson® Artificial Heart
BRIEF published on 07/01/2025 at 20:50, 1 year 3 months ago Half-yearly report on CARMAT's liquidity contract Liquidity Contract Actions CARMAT Judicial Recovery Stockbroker
BRIEF published on 06/20/2025 at 19:15, 1 year 4 months ago CARMAT launches a donation campaign in the face of a financial crisis Funding Heart Failure Artificial Heart Financial Crisis Donation Campaign
PRESS RELEASE published on 06/20/2025 at 19:10, 1 year 4 months ago Inside Information / Other news releases CARMAT launches a donation campaign to address critical financial situation and risk of insolvency. The initiative aims to secure urgent funding for its innovative total artificial heart Financial Situation CARMAT Artificial Heart Donation Campaign Risk Of Insolvency
BRIEF published on 06/04/2025 at 17:50, 1 year 4 months ago CARMAT: Terms and conditions for the General Meeting of June 26, 2025 General Assembly Remote Voting CARMAT Artificial Heart Financial Risks
BRIEF published on 06/02/2025 at 07:05, 1 year 4 months ago CARMAT makes its first sales of artificial hearts in Israel CARMAT European Union Israel Aeson® Locations
BRIEF published on 04/09/2025 at 17:50, 1 year 6 months ago CARMAT Achieves Strong Q1 2025 Results CARMAT Q1 2025 FDA Discussions Aeson® Implants EFICAS Trial
PRESS RELEASE published on 04/09/2025 at 17:45, 1 year 6 months ago Inside Information / Other news releases CARMAT delivers strong Q1 2025 results with €2.4m sales, progresses EFICAS trial, and advances FDA discussions for EFS study in the US. Aiming for long-term patient support with enhanced heart by end of 2025 CARMAT Long-term Support FDA Discussions Q1 2025 Results EFICAS Trial
BRIEF published on 02/17/2025 at 07:05, 1 year 8 months ago CARMAT's Aeson® Artificial Heart: Promising Results for Heart Failure with Pulmonary Hypertension Medical Innovation Heart Failure Treatment Aeson® Artificial Heart Pulmonary Hypertension Transplant Eligibility
PRESS RELEASE published on 02/17/2025 at 07:00, 1 year 8 months ago Inside Information / Other news releases CARMAT's Aeson® total artificial heart, featured in The Journal of Heart and Lung Transplantation, offers a promising solution for heart failure patients with pulmonary hypertension, potentially becoming a standard treatment Heart Failure CARMAT Aeson® Pulmonary Hypertension Transplant
Published on 10/23/2026 at 02:20, 9 hours 44 minutes ago Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 12 hours 34 minutes ago Cypher Announces Subscription Receipt Offering
Published on 10/22/2026 at 22:30, 13 hours 34 minutes ago Unusual Machines to Announce Third Quarter 2026 Financial Results and Provide Corporate Update
Published on 10/22/2026 at 16:00, 20 hours 4 minutes ago Future Fuels Announces Closing of Brokered Offering for Gross Proceeds of C$6.6 Million
Published on 10/22/2026 at 14:30, 21 hours 34 minutes ago Unusual Machines Receives $16.9 Million Purchase Order from Powerus for American-Made Drone Components
Published on 10/23/2026 at 11:45, 18 minutes ago Original-Research: Grand City Properties SA (von First Berlin Equity Research GmbH): Kaufen
Published on 10/23/2026 at 11:30, 34 minutes ago Bulgarian Financial Supervision Commission completes preliminary review of the voluntary public takeover offer for Shelly Group SE
Published on 10/23/2026 at 11:30, 34 minutes ago Acceptance period of Sazerac’s voluntary public takeover offer for Berentzen-Gruppe Aktiengesellschaft commences
Published on 10/23/2026 at 11:00, 1 hour 4 minutes ago Annual General Meeting Approves Contribution: Innok Robotics on Course for the Public Capital Market
Published on 10/22/2026 at 18:00, 18 hours 4 minutes ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 18 hours 4 minutes ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Published on 10/22/2026 at 18:00, 18 hours 4 minutes ago H1 2026: marked improvement in operating results
Published on 10/22/2026 at 17:47, 18 hours 16 minutes ago Aéroports de Paris SA - 2026 9-month revenue
